Hepatotoxicity after Sevoflurane Exposure in a Patient with Chronic Hepatitis C
Article Sidebar
Main Article Content
Abstract
Sevoflurane is considered a safe inhaled anesthetic of choice in patients with liver disease. Compared to other halogenated inhaled anesthetics, Sevoflurane is reported to lessen the severity of decreased hepatic blood flow and undergoes a different mechanism of hepatic metabolism. In patients with preexisting liver disease, there is potential for low-flow Sevoflurane to induce acute liver damage through other mechanisms. Limited data exists to guide clinical decision-making when quantifying the severity of cirrhosis in patients with hepatitis C and its relationship to anesthesia choice. Previous studies have found that exposure to general anesthesia during abdominal surgery may increase the risk of hepatorenal failure. This study has raised a concern that anesthetics may interfere with various hepatic functions secondary to viral infection. The generation of abnormal liver enzymes and hypercoagulation has provided further exploration for such toxicity.
Downloads
Article Details
Copyright (c) 2015 Shah N, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Liang TJ, Rehermann B, Seef LB, Hoofnagle JH (2000) Pathogenesis, natural History, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296-305.
Sherman KE (2011) Advanced Liver Disease: What every hepatitis C virus treater should know. Top Antiviral Med 19: 121-125.
Tong MJ, El-Farra NS, Reikes AR, Ruth L (1995) Clinical outcome after transfusion associated hepatitis C N Engl J Med 332: 1463-1466.
Gordon SC, Bayati N, Silverman A (1998) Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 23: 487-496 .
Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, et al. (1996) Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98: 1432-1440.
Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, et al. (2005) Comprehensive analysis of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepathology 42: 104-112.
Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, et al. (20004 An immune-modulatory rule for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40: 1062-1071.
Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, et al. (2005) Intrahepatic CD8+ T-cell failure duing chronic hepatitis C virus infection. Hepatology 42: 828-837.
Khan MH, Farrell GC, Byth K, Lin R, Weltman M, et al. (2000) Which Patients with Hepatitis C Develop Liver Complications? Hepatology 31: 513-520.
Poynard T, Bedossa P, Opolon P (1997) Natural History of liver fiborosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832.
Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, et al. (2001) The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presenece of alcohol abuse. Ann Intern Med 134: 120-124.
Ghaney MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, et al (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, et al (2006) Hepatitis C virus genotypes and virla concentrations in participants of a general population survey in the United States. Gastroenterology 131: 478-484.
Zekri AR, Bahnassy AA, Shaarawy SM, Mansour OA, Maduar MA, et al. (2000) Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 49: 89-85.
Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, et al. (2001) Sensitivity and specificity of third generation hepatitis C virus antibody detection assays: an analysis of the literature. J viral Hepat 8: 87-95.
Saldanha J, Lelie N, Heath A (1999) Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 76: 149-158.
Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, et al. (2000) Standardization of hepatitis C virus RNA amplification. Hepatology 32: 654-659.
Armstrong GL, Wasley A, Simard EP, McQUillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
Afdhal NH (2004) The natural history of hepatitis C. Semin Liver Dis 24: 3-8.
Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, et al. (2009) The model for end-stage liver disease score is the best prognostic factor in Human Immunodeficiency Virus 1-infected patients with end stage liver disease: A prospective cohort study. Liver Transpl 15: 1133-1141.
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403-409.
Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, et al. (1995) Ciprofloxacin and long term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 22: 1171-1174.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, et al. (2010) Rifaxmin treatment in hepatic encephalopathy. N Engl J Med 362: 1071-1081.
D'AMico G (1998) Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54: 650-671.
Sabry AA, Sobh MA, Irving WL, Grabowska A, Wagner BE, et al. (2002) A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 17: 239-245.
Dore MP, Fattovich G, Sepulveda AR, Realdi G (2007) Cryoglobulinemia releated to hepatitis C virus infection. Dig Dis Sci 52: 897-907.
Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, et al. (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49: 69-82.
Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327: 1490-1495.
Markowitz GS, Cheng JT, Colvin RB, Trebbin WM, D'Agati VD (1998) Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 9: 2244-2252.
Tang S, Lai KN (2005) Chronic viral hepatitis in hemodialysis patients. Hemodial Int 9: 169-179.
(1997) National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C: Hepatology 26: 25-105.
Yu JW, Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J gasroenterol Hepatol 22: 832-836.
Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, et al. (2006) A 24 week course of high dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 26: 1187-1195.
Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, et al. (2004) Interferon alfa-2b [correction of alpha-2b] and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 99: 1700-1705.
Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, et al. (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724-1732.
Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, et al. (1999) Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116: 135-143.
Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, et al. (1992) Immunity in hepatitis C infection. Limited humoral immunity in hepatitis C infection. J Infect Dis 165: 438-443 .
Mizorogi F, Hiramoto J, Nozato A, Takekuma Y, Nagayama K, et al. (2000) Hepatitis C virus infection in patients with B cell non-Hodgkin's Lymphoma. Intern Med 39: 112-117.
Alter H (2006) Viral Hepatitis. Hepatology 43: S230-234.
Ghobrial RM, Steadman R, Gornberg J, Lassman C, Holt CD, et al. (2001) A 10year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 234: 384-393.
Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, et al. (2004) Long term outcome of liver transplants for chronic hepatitis C: A 10 year follow up. Transplantation 77: 226-231.
Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, et al. (2004) Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41: 830-836.
Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, et al. (2007) A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 13: 975-983.
Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, et al. (2008) The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 21: 459-465.
Koziel MJ, Liang TJ (1994) Vaccination against hepatitis C virus infection: miles to go before we sleep [editorial]. Hepatology 20: 758-760.
Koziel M, Liang TJ (1997) DNA vaccines and viral hepatitis: are we going around in circles? Gastroenterology 112: 1410-1414.
Varnavski AN, Khromykh AA (1999) Noncytopathic flavivirus replicon RNA based system for expression and delivery of heterologous genes. Virology 255: 366-375.
Thomas DL, Seeff LB (2005) Natural History of hepatitis C. Clin Liver Dis 9: 383-398.
Strader DB, Seeff LB (1996) The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 8: 324-328.
Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36: S35-S46.
Nicoll A (2012) Surgical risk in patients with cirrhosis. Journal of Gastroenterology and Hepatology 27: 1569–1575.
Wilkins T, Malcolm J, Raina D, Schade R (2010) Hepatitis C: Diagnosis and Treatment. American Family Physician 81: 1351-1357.
Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, et al. (2005) External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. American J Gastroenterol 100: 868-873.
Hanje AJ, Patel T (2007) Preoperative evaluation of patients with liver disease. Nature Reviews Gastroenterology & Hepatology 4: 266-276.
Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM,, et al. (2007) Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 132: 1261-1269.
Keegan MT, Plevak DJ (2005) Preoperative Assessment of the Patient with Liver Disease. The American Journal of Gastroenterology 100: 2116- 2127.
Hanje AJ, Patel T (2007) Preoperative evaluation of patients with liver disease. Nature Clinical Practice Gastroenterology & Hepatology 4: 266-276.
Chelala E, Gaede F, Douillez V, Dessihy M, Alle JL (2003) The suturing concept for laparoscopic mesh fixation in ventral and incisional hernias: preliminary results. Hernia 7: 191–196.
Ramirez OM, Ruas E, Dellon AL (1990) “Components separation” method for closure of abdominal-wall defects: an anatomic and clinical study. Plast Reconstr Surg 86: 519–526.
Heniford BT, Park A, Ramshaw BJ, Voeller G (2003) Laparoscopic Repair of Ventral Hernias: Nine Years' Experience With 850 Consecutive Hernias. Ann Surg 238: 399–400.
Rives J, Lardennois B, Pire JC, Hibon J (1973) Les grandes eventrations:importance du ‘volet abdominal' et des troubles respiratoires qui lui sont sécondaires. Chirurgie 99: 547– 563.
Kingsnorth A (2006) The Management of Incisional Hernia. Ann R Coll Surg Engl 88: 252–260.
Alotaibi WM (2009) Severe Hepatic Dysfunction After Sevoflurane Exposure. Saudi Medical Journal 29: 1344-1346.
Martin JL (2005) Volatile Anesthetics and Liver Injury: a Clinical Update or What Every Anesthesiologist Should Know. Canadian Journal of Anesthesia 52: 125-129.
Kim JW, Kim JD, Yu SB, Ryu SJ (2013) Comparison of Hepatic and Renal Function Between Anesthesia and Sevoflurane and Remifentanil and Total Intravenous Anesthesia with Propofol and Remifentanil for Thyroidectomy. Korean Journal Anesthesiology 112-116.
Obata R, Bito H, Ohmura M, Moriwaki G, Ikeuchi Y, et al. (1993) The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesthesiology 79: 795-807.
Singhal S, Gray T, Guzman G, Verma A, Anand K (2010) Sevoflurane Hepatotoxicity: a case report of sevoflurane Hepatic necrosis and review of the literature. American Journal of Therapeutics 17: 219-222.
Hoetzel A, Leitz D, Schmidt R, Tritschler E, Bauer I, et al. (2006) Mechanism of Hepatic Heme Oxygenase-1 Induction by Isoflurane. Anesthesiology 104: 101-109.
Liu SJ, Li Y, Sun B, Wang Cs, Gong YL, et al. (2012) Sofnolime with Different Water Content Causes Different Effects in Two Sevoflurane Inhalational Induction Techniques with Respect to the Output of Compound-A. Int J Med Sci 9: 435-440.